2007
DOI: 10.1016/j.cvsm.2007.01.010
|View full text |Cite
|
Sign up to set email alerts
|

Thromboembolic Therapies in Dogs and Cats: An Evidence-Based Approach

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
60
2
1

Year Published

2010
2010
2024
2024

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 49 publications
(63 citation statements)
references
References 142 publications
0
60
2
1
Order By: Relevance
“…Successful thrombolytic therapy with streptokinase (Ramsey et al 1996) and recombinant tissue plasminogen activator (Clare and Kraje 1998) has been reported in cases of canine aortic thromboembolism. Nonetheless, severe hyperkalaemia can develop as a reperfusion injury after thrombolytic therapy in dogs and cats with AT (Schoeman 1999;Lunsford and Mackin 2007). In the present case, initial thrombotic management was recommended, but the owner declined because of side effects and for financial reasons.…”
Section: Discussionmentioning
confidence: 86%
“…Successful thrombolytic therapy with streptokinase (Ramsey et al 1996) and recombinant tissue plasminogen activator (Clare and Kraje 1998) has been reported in cases of canine aortic thromboembolism. Nonetheless, severe hyperkalaemia can develop as a reperfusion injury after thrombolytic therapy in dogs and cats with AT (Schoeman 1999;Lunsford and Mackin 2007). In the present case, initial thrombotic management was recommended, but the owner declined because of side effects and for financial reasons.…”
Section: Discussionmentioning
confidence: 86%
“…The role of the fibrinolytic system in the pathogenesis of hyper-coagulability has been addressed and partially recognized in human medicine (Lunsford and Mackin 2007). The presence of TAT complex is a good indicator of thrombin generation in vivo and is a sensitive marker of hypercoagulation.…”
Section: Hypercoagulabilitymentioning
confidence: 99%
“…Metabolic diseases, such as protein-losing nephropathy (PLN), may increase the presence of hypercoagulable factors in blood, especially TXA 2 and fibrinogen (Littman et al 2000, Lunsford andMackin 2007). Proteinuria leads to hypoalbuminaemia hypercholesterolaemia and polycythaemia, which is the basis for decreasing of the plasma volume, thereby generating platelet-platelet contact and hyper-aggregability.…”
Section: Hypercoagulabilitymentioning
confidence: 99%
See 1 more Smart Citation
“…Medical treatment aimed at thromboembolic diseases consists of dissolving existing thrombi (thrombolytic drugs) or preventing new thrombus formation, primarily by means of the use of antiplatelet drugs, heparin products, and vitamin K antagonist. Streptokinase is the most common thrombolytic drug and causes thrombolysis by accelerating activation of fibrin-bound plasminogen to plasmin [10,11]. Three meta-analyses compared the mortality and amputation rates in human patients with acute limb ischemia undergoing thrombolytic therapy or surgical vascular restoration.…”
mentioning
confidence: 99%